RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
Status:
RECRUITING
Trial end date:
2028-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.